

CA Keyur Shah FCA, B.Com, ISA,

Limited Review Report on unaudited consolidated financial results of Sotac Pharmaceutical Certified Limited for the Quarter ended 30 June 2023 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To, The Board of Directors of, Sotac Pharmaceutical Limited (Formerly Known As Sotac Pharmaceutical Private Limited)

We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results ("the Statement") of **Sotac Pharmaceutical Limited** ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2023, being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down as per Accounting Standards, Prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

The Statement includes the results of the following entities:

1. Sotac Pharmaceutical Limited ("Parent")

SHAH

- 2. Sotac Healthcare Private Limited ("Subsidiary")
- 3. Sotac Lifesciences Private Limited ("Subsidiary")
- 4. Sotac Research Private Limited ("Subsidiary")

Based on our review conducted and procedures performed as stated in above and based on the statement provided by the Management related to Parent & Subsidiary, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of

303, Shitiratna, B/s. Radisson Blu Hotel Ar, Parchvati Circle, Ambawadi, Ahmedabad-380006. Gujarat, INDIA. Ph. : +91 79 48999595 M : +91 999 8484 564 • Website : www.keyurshahca.com E-mail : keyur@keyurshahca.com.ca.keyurshah2015@gmail.com Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

We did not review the interim financial statements / financial information / financial results of Subsidiaries i.e. Sotac Healthcare Private Limited ("Subsidiary")/ Sotac Lifesciences Private Limited ("Subsidiary")/ Sotac Research Private Limited ("Subsidiary") included in the consolidated unaudited financial results, whose interim financial statements / financial information / financial results reflect total revenues of Rs. 101.89 Lakhs and total net profit/(loss) after tax of Rs. (22.16) Lakhs for the quarter ended June 30, 2023, respectively, as considered in the consolidated unaudited financial results have not been reviewed by us. These interim financial statements / financial information / financial results have been reviewed by the Auditor of respective subsidiary company and provided by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiary is based solely on the reports provided by the Management and the procedures performed by us as stated in above paragraph.

Our conclusion on the statement is not modified in respect of the above matters.

SHAH

DACCO

For, Keyur Shah & Co. Chartered Accountants F.R.No. 141173W

Keyur Shah Proprietor M. No. 153774 UDIN: -23153774BGWLXX1531

Date: - 11th August, 2023 Place: - Ahmedabad

Sr no.						(INR in Lakhs unless oth	erwise Specified)
no.	Particulars		20.05.202	2 1	Quarter ended 31.03.2023		Year ended
_	Particulars		30.06.202 Unaudite		Audited	30.06.2022 Unaudited	31.03.2023 Audited
	EVENUE FROM OPERATIONS			96.70	1808.39	1986.96	7748.3
	DTHER INCOME			22.99	13.62	6.93	34.9
1224	OTAL REVENUE (I + II)		25	19.69	1822.01	1993.89	7783.2
	<u>XPENSES</u> ost of Material Consumed		17	87.67	1473.34	1605.43	6115.2
b) P	urchase of Stock-in-Trade			8.05	13.00	2.32	52,6
	hanges in Inventories of Finished Goods/ Work-In-Pi mployee Benefit Expenses	rogress/ Stock in Trade		26.16) 97.78	(291.88) 112.39	(61.59) 88.39	(440.9) 422.7
e) F	inance Costs			45.82	64.10	29.47	197,5
	epreciation and Amortisation Expense. Ither Expenses		1 C C C C C C C C C C C C C C C C C C C	60.44 95.77	60.62 259.73	49.96 160.74	227.7 873.6
~10	OTAL EXPENSES (IV)			69.37	1691.30	1874.72	7448.6
1.11	ROFIT/(LOSS) BEFORE EXCEPTIONAL & EXTRAORDI	NARY ITEMS & TAX (III - IV)		50.32	130.71	119.±7	334.6
	xceptional/Prior Period Items						58.0
1.0.1	ROFIT BEFORE EXTRAORDINARY ITEMS & TAX (V-V	1)	1	50.32	130.71	119.17	392.6
	xtraordinary Items			20			
1.6	ROFIT BEFORE TAX (VII-VIII)		1	50.32	130.71	119.17	.392.6
х) т	AX EXPENSE						
·	urrent Tax		1.23	45.92	48.87	70.08	168.3
	Deferred Tax			6.00	(21.73)	(4.57)	(4.3
τ	OTAL TAX EXPENSE (X)			51.92	27.14	65.51	164.0
12	ROFIT / (LOSS) FOR THE PERIOD/YEAR (IX-X)			98.40	103.57	53.66	228.6
(II) P.	aidup Equity Share Capital (Face value Rs 10 each)		11	05.00	805.00	230.00	805.0
						200100.00000.00	102.0
(III) R	eserve & Surplus (Excluding Revaluation Reserve)						193.8
IV) E	ARNINGS PER EQUITY SHARE-BASIC/DILUTED					12	
	asic /Diluted earnings per share (In INR) tot annualised, for the quarter ended)			0.92	1.29	2.33	2.8
ded o	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped	e Balancing figures betwee view.		ed out by respect o	the statutory auditors of full financial year and	of the company .	
, ded o] The f] The (] Com rup an]The H	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering	ne Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatii (IPO) of 30,00,000 equity s	en the audited figures in ted wherever considered Il results for the quarter of products such as Non Be ng under single segment hares of face value of Rs	ed out by respect o I necessar ended 30t ta-Lactam hence sep . 10/- eacl	the statutory auditors of f full financial year and Y. h June 2023. t (general) tablets, Non gment reporting is not a h fully paid up for cash	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe	up to the third quar psules, Non Beta-lact er equity share{includ
ded o] The f] The C] Com rup an]The H are pr	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share} aggregating to f	ne Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatii (IPO) of 30,00,000 equity s	en the audited figures in ted wherever considered Il results for the quarter of products such as Non Be ng under single segment hares of face value of Rs	ed out by respect o I necessar ended 30t ta-Lactam hence sep . 10/- eacl	the statutory auditors of f full financial year and Y. h June 2023. t (general) tablets, Non gment reporting is not a h fully paid up for cash	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe	up to the third quar psules, Non Beta-lact er equity share(includ
, ded o The f The f Com rup an The H are pr atform	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering	the Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s ts,3330.00/- Lakhs. The afo	en the audited figures in ted wherever considered of results for the quarter products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar	ed out by respect o ended 30t ta-Lactam hence sej 10/- eacl res of the	the statutory auditors α f full financial year and γ. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Eme
, ded o The f The f Com Com rup an Tup an The H are pr atform	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023.	ne Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operation (IPO) of 30,00,000 equity s Rs.3330.00/- Lakhs. The ard f the Holding company had	en the audited figures in ted wherever considered of results for the quarter of products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99;	ed out by respect o I necessar ended 30t ta-Lactam hence seg 10/- eac res of the 50,000 eq	the statutory auditors of f full financial year and Y. h June 2023. I (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Eme
, ded o The f The f Com rup an The H are pr atform The S Rs. 10	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private Limited "The Subsidiary" o	the Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s iss,3330.00/- Lakhs. The afo f the Holding company had ting to Rs.99.50/- Lakhs. The	en the audited figures in ited wherever considered al results for the quarter of products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of	ed out by respect o I necessar ended 30t ta-Lactam hence seg 10/- eac res of the 50,000 eq	the statutory auditors of f full financial year and Y. h June 2023. I (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and g e of Rs. 10/- each fully pa lay, 2023.	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Emei nid up for cash at a pr
ded o The f The f The C Com rup an The H are pr atform The S Rs. 10	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregat he Status of investor's complaints during the year en	the Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s iss,3330.00/- Lakhs. The afo f the Holding company had ting to Rs.99.50/- Lakhs. The	en the audited figures in ited wherever considered al results for the quarter of products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of	ed out by respect o I necessar ended 30t ta-Lactam hence seg 10/- eac res of the 50,000 eq	the statutory auditors of f full financial year and Y. h June 2023. I (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and g e of Rs. 10/- each fully pa lay, 2023.	up to the third quar psules, Non Beta-lacta er equity share(includi at listed on NSE Emer nid up for cash at a pr
Inded o The f The f The f Comp rup an The H are pr atform The S Rs. 10 The S Co	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregat the Status of investor's complaints during the year en omplaints pending at the beginning of the period omplaints received during the period	the Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s iss,3330.00/- Lakhs. The afo f the Holding company had ting to Rs.99.50/- Lakhs. The	en the audited figures in ited wherever considered al results for the quarter of products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eact res of the 50,000 eq equity sha Nill 1	the statutory auditors of f full financial year and Y. h June 2023. I (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa	up to the third quar psules, Non Beta-lacta er equity share(includi at listed on NSE Emer nid up for cash at a pri
inded o The f The f Comp The H The H are pr The S Rs. 10 Th Cc Cc Cc	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. Otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregating to Status of investor's complaints during the year en omplaints pending at the beginning of the period amplaints disposed during the period	the Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s iss,3330.00/- Lakhs. The afo f the Holding company had ting to Rs.99.50/- Lakhs. The	en the audited figures in ited wherever considered al results for the quarter of products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of	ed out by respect o f necessar ended 30t ta-Lactam hence sej . 10/- eacl res of the 50,000 eq equity sha Nill 1 1	the statutory auditors of f full financial year and Y. h June 2023. I (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and g e of Rs. 10/- each fully pa lay, 2023.	up to the third quar psules, Non Beta-lacta er equity share(includi at listed on NSE Emer nid up for cash at a pri
inded o The f The f Comp The H The H are pr The S Rs. 10 Th Cc Cc Cc	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregat the Status of investor's complaints during the year en omplaints pending at the beginning of the period omplaints received during the period	the Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s iss,3330.00/- Lakhs. The afo f the Holding company had ting to Rs.99.50/- Lakhs. The	en the audited figures in ited wherever considered al results for the quarter of products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eact res of the 50,000 eq equity sha Nill 1	the statutory auditors of f full financial year and Y. h June 2023. I (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and g e of Rs. 10/- each fully pa lay, 2023.	up to the third quar psules, Non Beta-lacta er equity share(includi at listed on NSE Emer nid up for cash at a pri
Inded o I The f The f Comp The H The S The S Rs. 10 The S Ca Ca Ca Ca Ca Ca Ca Ca Ca Ca	figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. Otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregating to Status of investor's complaints during the year en omplaints pending at the beginning of the period amplaints disposed during the period	the Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s iss,3330.00/- Lakhs. The afo f the Holding company had ting to Rs.99.50/- Lakhs. The	en the audited figures in ited wherever considered Il results for the quarter of products such as Non Be- ng under single segment hares of face value of Rs rementioned equity share Il made Right Issue of 99, e abovementioned right of der:-	ed out by respect o f necessar ended 30t ta-Lactam hence sej . 10/- eact res of the 50,000 eq equity sha Nill 1 1 Nill	the statutory auditors of f full financial year and γ. (h June 2023: I (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o nuity shares of face valu re alloted as on 11th M	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023.	up to the third quar psules, Non Beta-lacta er equity share(includi at listed on NSE Emer nid up for cash at a pr
Inded o I The f The f Comp The H The S The S Rs. 10 The S Ca Ca Ca Ca Ca Ca Ca Ca Ca Ca	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregat te Status of investor's complaints during the year en omplaints pending at the beginning of the period amplaints disposed during the period amplaints resolved at the end of the period	the Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s iss,3330.00/- Lakhs. The afo f the Holding company had ting to Rs.99.50/- Lakhs. The	en the audited figures in ited wherever considered al results for the quarter of products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eacl res of the 50,000 eq equity sha Nill 1 Nill son	the statutory auditors of f full financial year and Y. h June 2023. I (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and g e of Rs. 10/- each fully pe lay, 2023. Directly or Indirectly	up to the third quart psules, Non Beta-lacta er equity share(includi at listed on NSE Emer nid up for cash at a pri
I the f The f The f The f Comp Trup an The H are pr atform The S Rs. 10 The S Cc Cc Cc Cc Cc Cc Cc Cc Cc Cc	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregat te Status of investor's complaints during the year en omplaints pending at the beginning of the period amplaints resolved at the end of the period amplaints resolved at the end of the period at the Entities Consolidated in the Statement: Name of the Subsidiares Companies tac Healthcare Private Limited	The Balancing figures betwee riew. / rearranged and / or recass olidated unaudited financia le range of pharmaceutical usiness company is operatin (PO) of 30,00,000 equity s ts.3330.00/- Lakhs. The afo f the Holding company hac ting to Rs.99.50/- Lakhs. The ded on June 30,2023 as un Relationship Subsidary	en the audited figures in ted wherever considered I results for the quarter in products such as Non Be- ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of der:- % of Holding a: 30-06-2023 2	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eaci so,000 eq equity sha Nill 1 Nill 1 Nill 3 Nill 1 7 1.00	the statutory auditors of f full financial year and y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o uity shares of face valu ire alloted as on 11th M voting Power Either I <u>through Su</u> Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly ibsidaries ctly	psules, Non Beta-lacta rr equity share(includii ot listed on NSE Emer ild up for cash at a pri
] The f] The f] The f] Common and the formation of the	Figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b- loolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f- on 13th April, 2023. otac Lifesciences Private Limited "The Subsidiary" o- /- per equity share (Security Premium- NIL) aggregating to Status of investor's complaints during the year en- omplaints pending at the beginning of the period amplaints resolved at the end of the period amplaints resolved at the end of the period st of the Entities Consolidated in the Statement:: Name of the Subsidiaries Companies tac Healthcare Private Limited	e Balancing figures betwee riew. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s iss,3330.00/- Lakhs. The afo f the Holding company hac ting to Rs.99.50/- Lakhs. Thi ded on June 30,2023 as un Relationship Subsidary Subsidary	en the audited figures in ited wherever considered Il results for the quarter of products such as Non Be- ng under single segment hares of face value of Rs rementioned equity shar Il made Right Issue of 99, e abovementioned right of der:	ed out by respect o f necessar ended 30t ta-Lactam hence sej . 10/- eact res of the 50,000 eq equity sha Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 Nill 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	the statutory auditors of f full financial year and y. (h June 2023) is (general) tablets, Non grent reporting is not a h fully paid up for cash e company alloted as o uity shares of face valu re alloted as on 11th M voting Power Either (through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lacta er equity share(includi at listed on NSE Emer nid up for cash at a pri
) The f) The f) Communication of the formula of	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregat the Status of investor's complaints during the year en omplaints pending at the beginning of the period implaints resolved at the end of the period implaints resolved at the end of the period st of the Entities Consolidated in the Statement: Name of the Subsidiaries Companies tac Healthcare Private Limited tac Research Private Limited tac Lifesciences Private Limited tac Lifesciences Private Limited	e Balancing figures betwee riew. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical usiness company is operatii (PO) of 30,00,000 equity s Rs.3330.00/- Lakhs. The afo f the Holding company hac ting to Rs.99.50/- Lakhs. The ded on June 30,2023 as un Relationship Subsidary Subsidary Subsidary	en the audited figures in ted wherever considered Il results for the quarter i products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar Il made Right Issue of 99, e abovementioned right of der:- % of Holding at 30-06-2023 7 10 5	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eaci tso,000 eq equity sha Nill 1 1 Nill 1 1 Nill 1 1 1 Nill 1 1 1 1 1 0 0 000 eq equity sha	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Emei nid up for cash at a pr
) The f) The f) The f) Comm rup an IThe H are pr the form IThe S Rs. 10 I The S Cc Cc Cc Cc Sc Sc Sc Sc Sc	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to an 13th April, 2023. otac Lifesciences Private Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregat the Status of investor's complaints during the year en complaints received during the period amplaints received during the period amplaints received during the period amplaints recolved at the end of the period st of the Entities Consolidated in the Statement: Name of the Subsidiaries Companies tac Healthcare Private Limited tac Research Private Limited tac Research Private Limited tac Ufesciences Private Umited tac Private Umited tac Ufesciences Private Umited tac Ufesciences Private Umited tac Ufesciences Private Umited tac Ufesciences Private Umited tac Private Umited tac Ufesciences Private	e Balancing figures betwee riew. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical usiness company is operatii (PO) of 30,00,000 equity s Rs.3330.00/- Lakhs. The afo f the Holding company hac ling to Rs.99.50/- Lakhs. The ded on June 30 ,2023 as un Relationship Subsidary Subsidary Subsidary Subsidary Subsidary Subsidary	en the audited figures in ted wherever considered of results for the quarter of products such as Non Be ng under single segment hares of face value of Rs rementioned equity shares of made Right Issue of 99, e abovementioned right of der:- % of Holding ar 30-06-2023 10 5 akhs. The Object for the	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eaci res of the 50,000 eq equity sha Nill 1 1 Nill 1 1 Nill 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Emei nid up for cash at a pr
The formation of the second se	Figures for the quarter ended 31 March 2023 are the n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b loolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregating to Status of investor's complaints during the year en omplaints pending at the beginning of the period amplaints resolved at the end of the period amplaints resolved at the end of the period at the Entities Consolidated in the Statement: Name of the Subsidaries Companies tac Healthcare Private Limited tac Research Private Limited tac Lifesciences Private Limited tac Private Limited tac Lifesciences Private Limited	e Balancing figures betwee riew. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical usiness company is operatil (IPO) of 30,00,000 equity s ts,3330.00/- Lakhs. The afo f the Holding company hac ting to Rs.99.50/- Lakhs. The ded on June 30,2023 as un Relationship Subsidary S	en the audited figures in ted wherever considered I results for the quarter of products such as Non Be- ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99; e abovementioned right of der:	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eaci so,000 eq equity sha Nill 1 Nill 1 Nill 1 Nill 1 Nill 1 1 Ni 1 Ni	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Emei nid up for cash at a pr
The form of the second	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid- d external preparations looking into the nature of b- loiding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f- on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o- /- per equity share (Security Premium- NIL) aggregating the Status of investor's complaints during the year en- mplaints received during the period amplaints received at the end of the period amplaints resolved at the end of the period st of the Entities Consolidated in the Statement: Name of the Subsidaries Companies tac Research Private Limited tac Research Private Limited tac Research Private Limited tac Lifesciences Private Limited tac Lifesciences Private Limited tac Lifesciences Private Limited tac Lifesciences Private Limited tac Research Private Limited tac Lifesciences Private Limited tac Proceeds from the IPO before Net off Issue relaterer Private Limited	e Balancing figures betwee view. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical le range of pharmaceutical usiness company is operatii (IPO) of 30,00,000 equity s ks.3330.00/- Lakhs. The afor f the Holding company had ing to Rs.99.50/- Lakhs. The ded on June 30 ,2023 as un Relationship Subsidary Subsidary Subsidary Subsidary Subsidary d expenses is RS. 3,330.00 L Planned As per Prospectus	en the audited figures in ted wherever consideree il results for the quarter i products such as Non Be ng under single segment hares of face value of RS rementioned equity shar I made Right Issue of 99, e abovementioned right of der:- % of Holding at 30-06-2023 1 1 2 3 akhs. The Object for the	ed out by respect o f necessar ended 30t ta-Lactam hence seg 10/- eacl res of the 50,000 eq equity sha Nill 1 Nill Son 50,000 eq equity sha Nill 1 Nill 1 Nill son 51,00 50,000 eq equity sha son 51,000 51,0000000000	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Emei nid up for cash at a pr
) The f) The f) Communication of the form (The H are printform (The S are printform (The S are printform (The S are printform) (The S are printform) (figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregating to first spending at the beginning of the period implaints received during the period implaints resolved at the end of the period implaints resolved at the end of the period st of the Entities Consolidated in the Statement: Name of the Subsidiaries Companies tac Healthcare Private Limited tac Research Private Limited tac Elesciences Private Limited tac Elesciences Private Limited tac Lifesciences Private Limited tac Besearch Private Limited tac Lifesciences Private Limited tac Lifescien	e Balancing figures betwee view. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical le range of pharmaceutical usiness company is operatii (IPO) of 30,00,000 equity s ks.3330.00/- Lakhs. The afor f the Holding company had ing to Rs.99.50/- Lakhs. The ded on June 30 ,2023 as un Relationship Subsidary Subsidary Subsidary Subsidary Subsidary d expenses is RS. 3,330.00 L Planned As per Prospectus	en the audited figures in ted wherever consideree il results for the quarter i products such as Non Be ag under single segment hares of face value of RS rementioned equity shar I made Right Issue of 99, e abovementioned right of der:-	ed out by respect o f necessar ended 30t ta-Lactam hence seg 10/- eacl res of the 50,000 eq equity sha Nill 1 1 Nill Son 1 1.00 00.00 11.26 are as foll res to	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Emei nid up for cash at a pr
I the formation of the second	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b- loolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f- on 13th April, 2023. otac Lifesciences Private Limited "The Subsidiary" o- /- per equity share (Security Premium- NIL) aggregating te Status of investor's complaints during the year en- boxed at the beginning of the period amplaints received during the period amplaints resolved at the end of the period amplaints resolved at the end of the period st of the Entities Consolidated in the Statement: Name of the Subsidaries Companies tac Healthcare Private Limited tac Research Private Limited tac Lifesciences Private Limited tac Lifesciences Private Limited tac Besearch Private Limited tac Research Private Limited tac To Meet Working Capital Requirements a a To Meet Working Capital Requirements b Investment in Subsidiary a Lipgradation / Construction of Existing	e Balancing figures betwee view. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical le range of pharmaceutical usiness company is operatii (IPO) of 30,00,000 equity s Rs.3330.00/- Lakhs. The afo f the Holding company hac ing to Rs.99.50/- Lakhs. Thi ded on June 30 ,2023 as un Relationship Subsidary Subsid	en the audited figures in ted wherever considered il results for the quarter i products such as Non Be ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of der:	ed out by respect o f necessar ended 30t ta-Lactam hence seg 10/- eacl res of the 50,000 eq equity sha Nill 1 1 Nill Son 1 71.00 0.00 51.26 are as foll res to ised	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Emei nid up for cash at a pr
Inded o The f The f Company Trup and The S Arrow of the S Company The S Company The S Company The S Company Company The S Company The S Company Co	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid- d external preparations looking into the nature of b- loiding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f- on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o- /- per equity share (Security Premium- NIL) aggregating the Status of investor's complaints during the year en- torplaints pending at the beginning of the period amplaints received during the period amplaints received at the end of the period amplaints resolved at the end of the period amplaints received at the end of the period amplaints received at the end of the period tac Healthcare Private Limited tac Research Private Limited tac Research Private Limited tac Research Private Limited tac Research Private Limited tac Lifesciences Private Limited tac Lifesciences Private Limited tac Lifesciences Private Limited tac Research Private Limited tac Research Private Limited tac Lifesciences Private Limited tac Discourd from the IPO before Net off Issue relater r. Particulars a To Meet Working Capital Requirements b Investment in Subsidiary	e Balancing figures betwee riew. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical usiness company is operatii (PO) of 30,000 equity s Rs.3330.00/- Lakhs. The afd f the Holding company hac ing to Rs.99.50/- Lakhs. Thi ded on June 30 ,2023 as un Relationship Subsidary Subsidary Subsidary Subsidary Subsidary d expenses is RS. 3,330.00 L Planned As per Prospectus 1,080.00 700.00 590.01 739.99	en the audited figures in ted wherever considered il results for the quarter i products such as Non Be ag under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99, e abovementioned right of der:-	ed out by respect o f necessar ended 30t ta-Lactam hence sej res of the 50,000 eq equity sha Nill 1 1 Nill 1 Nill 1 Nill 1 Nill Nill	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid up for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Emei nid up for cash at a pr
I The f The f The f Company The H are pr The S Rs. 100 The S S S S S S S S S S S S S S	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregating to Status of investor's complaints during the year en bomplaints pending at the beginning of the period amplaints resolved at the end of the period amplaints resolved at the end of the period amplaints resolved at the end of the period at the Entities Consolidated in the Statement: Name of the Subsidiaries Companies tac Healthcare Private Limited tac Research Private Limited tac Elesciences Private Limited tac Lifesciences Private Limited tac General Corporate Purpose Public Issue Expenses	e Balancing figures betwee riew. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical usiness company is operatii (PO) of 30,00,000 equity s ts.3330.00/- Lakhs. The afo f the Holding company hac ting to Rs.99.50/- Lakhs. The ded on June 30,2023 as un Relationship Subsidary Su	en the audited figures in ted wherever considered I results for the quarter of products such as Non Be- ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99; e abovementioned right of der:	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eaci so,000 eq equity sha Nill 1 1 Nill Son 71.00 00.00 61.26 are as foll res o stor sed	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid of for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third quar psules, Non Beta-lact er equity share(includ ot listed on NSE Eme nid up for cash at a pr
ded o ded o The f The f Compupant The H Interpreterror The S Rs. 10 The S Rs. 10 The S Compute	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons- pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b lolding company had made an initial public offering emium of Rs. 101 per equity share) aggregating to on 13th April, 2023. otac Lifesciences Private Limited "The Subsidiary" o /- per equity share (Security Premium-NIL) aggregat te Status of investor's complaints during the year en omplaints received during the period amplaints received furing the period amplaints received at the end of the period amplaints received furing the period amplaints received the end of the period amplaints received the end of the period amplaints received the period furing the period amplaints received the period furing the period ampla the period furing the period	e Balancing figures betwee riew. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical usiness company is operatii (PO) of 30,000 equity s Rs.3330.00/- Lakhs. The afd f the Holding company hac ing to Rs.99.50/- Lakhs. Thi ded on June 30 ,2023 as un Relationship Subsidary Subsidary Subsidary Subsidary Subsidary d expenses is RS. 3,330.00 L Planned As per Prospectus 1,080.00 700.00 590.01 739.99	en the audited figures in ted wherever considered of results for the quarter of products such as Non Be ag under single segment hares of face value of Rs rementioned equity shar of made Right Issue of 99, e abovementioned right of der:	ed out by respect o f necessar ended 30t ta-Lactam hence sej 10/- eaci so,000 eq equity sha Nill 1 1 Nill Son 71.00 00.00 61.26 are as foll res o stor sed	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid of for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 111/- pe n 10th April, 2023 and gi e of Rs. 10/- each fully pa lay, 2023. Directly or Indirectly thy ctly	up to the third qua psules, Non Beta-lact er equity share(includ ot listed on NSE Eme nid up for cash at a pi
ded o ded o The f The f Compupant The H Interpreterror The S Rs. 10 The S Rs. 10 The S Compute	figures for the quarter ended 31 March 2023 are th n 31 december 2022 which are sujbect to limited re- igures of the previous period have been re-grouped Company has Voluntarily adopted the quarterly cons pany is mainly engaged in manufacturing of of a wid d external preparations looking into the nature of b looling company had made an initial public offering emium of Rs. 101 per equity share) aggregating to f on 13th April, 2023. otac Lifesciences Private, Limited "The Subsidiary" o /- per equity share (Security Premium- NIL) aggregating to Status of investor's complaints during the year en omplaints pending at the beginning of the period amplaints resolved at the end of the period amplaints resolved at the end of the period amplaints resolved at the end of the period at the Entities Consolidated in the Statement: Name of the Subsidiaries Companies tac Healthcare Private Limited tac Research Private Limited tac Elesciences Private Limited tac Lifesciences Private Limited tac General Corporate Purpose Public Issue Expenses	e Balancing figures betwee riew. / rearranged and / or recas olidated unaudited financia le range of pharmaceutical usiness company is operatii (PO) of 30,00,000 equity s ts.3330.00/- Lakhs. The afo f the Holding company hac ting to Rs.99.50/- Lakhs. The ded on June 30,2023 as un Relationship Subsidary Su	en the audited figures in ted wherever considered I results for the quarter of products such as Non Be- ng under single segment hares of face value of Rs rementioned equity shar I made Right Issue of 99; e abovementioned right of der:	ed out by respect o f necessar ended 30t ta-Lactam hence seg 10/- eacl res of the 50,000 eq equity sha Nill 1 1 Nill Son 50,000 eq equity sha Nill 1 1 Nill 1 Nill 1 1 Nill 1 1 Nill Nill	the statutory auditors of f full financial year and Y. h June 2023. i (general) tablets, Non gment reporting is not a h fully paid of for cash e company alloted as o juity shares of face valu re alloted as on 11th M Voting Power Either I through Su Dire Dire	of the company . I the year-to-date figures Beta-Lactam (general) ca applicable to Company. at a price of Rs. 11/- pe n 10th April, 2023 and ge e of Rs. 10/- each fully pe lay, 2023. Directly or Indirectly thisidaries tty tty Charles Company. Directly or Indirectly thisidaries tty Classical Company. Classical Company. Classica	up to the third qua psules, Non Beta-lact er equity share(includ ot listed on NSE Eme nid up for cash at a pi

Place : Ahmedabad Date : 11th August, 2023